Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Share-based Compensation came in at $86.6 million in Q2 2026, down 22.43% YoY from $111.7 million in Q2 2025, and up 23.48% on a QoQ basis from $70.2 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Share-based Compensation (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Share-based Compensation data on file, last reported at $86.6 million in Q2 2026.
- Quarterly Share-based Compensation fell 22.43% year-over-year to $86.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $336.6 million (up 10.06% YoY) and the FY2025 annual result came in at $348.2 million, up 27.99% from the prior year.
- Share-based Compensation rose to $86.6 million in Q2 2026, from $70.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $128.1 million in Q3 2022 to a low of $29.3 million in Q1 2022.
- A 5-year average of $68.3 million and a median of $67.0 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 283.97% — and 2023, when it slumped 50.1%.
- Tracing ALNY's Share-based Compensation over 5 years: stood at $42.8 million in 2022, then retreated by 1.81% to $42.0 million in 2023, then soared by 118.23% to $91.6 million in 2024, then retreated by 21.84% to $71.6 million in 2025, then climbed by 20.93% to $86.6 million in 2026.
- The last three Share-based Compensation figures came in at $86.6 million (Q2 2026), $70.2 million (Q1 2026), and $71.6 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 83.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.63 Mn |
| Jun 30, 2026 | 86.63 Mn |
| Mar 31, 2026 | 70.15 Mn |
| Mar 31, 2026 | 70.15 Mn |
| Dec 31, 2025 | 71.63 Mn |
| Dec 31, 2025 | 71.63 Mn |
| Sep 30, 2025 | 268.07 Mn |
| Sep 30, 2025 | 268.07 Mn |
| Jun 30, 2025 | -1.29 Mn |
| Jun 30, 2025 | -1.29 Mn |
| Mar 31, 2025 | 9.83 Mn |
| Mar 31, 2025 | 9.83 Mn |
| Dec 31, 2024 | -171.13 Mn |
| Dec 31, 2024 | -171.13 Mn |
| Sep 30, 2024 | 45.80 Mn |
| Sep 30, 2024 | 45.80 Mn |
| Jun 30, 2024 | 133.86 Mn |
| Jun 30, 2024 | 133.86 Mn |
| Mar 31, 2024 | 774,000.00 |
| Mar 31, 2024 | 774,000.00 |